Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2 and CDK9. It shows promise in oncology for disrupting cancer cell proliferation by inducing cell cycle arrest and apoptosis. Its structure allows for high binding affinity to the ATP-binding site of CDKs, making it a valuable scaffold in developing anti-cancer agents. Also employed in biochemical assays to study transcriptional regulation, as CDK9 inhibition affects RNA polymerase II activity. Due to its bromobenzyl moiety, it can be further modified for probe development or conjugation in target identification studies.